98 related articles for article (PubMed ID: 22047802)
21. Reversible and noncompetitive inhibition of beta-tryptase by protein surface binding of tetravalent peptide ligands identified from a combinatorial split-mix library.
Wich PR; Schmuck C
Angew Chem Int Ed Engl; 2010 Jun; 49(24):4113-6. PubMed ID: 20432495
[No Abstract] [Full Text] [Related]
22. Bivalent inhibition of human beta-tryptase.
Schaschke N; Matschiner G; Zettl F; Marquardt U; Bergner A; Bode W; Sommerhoff CP; Moroder L
Chem Biol; 2001 Apr; 8(4):313-27. PubMed ID: 11325588
[TBL] [Abstract][Full Text] [Related]
23. Novel pyrazinone inhibitors of mast cell tryptase: synthesis and SAR evaluation.
Hopkins C; Neuenschwander K; Scotese A; Jackson S; Nieduzak T; Pauls H; Liang G; Sides K; Cramer D; Cairns J; Maignan S; Mathieu M
Bioorg Med Chem Lett; 2004 Oct; 14(19):4819-23. PubMed ID: 15341931
[TBL] [Abstract][Full Text] [Related]
24. cDNA cloning and substrate specificity of equine tryptase, a possible mediator in equine heaves.
Dacre KJ; McAleese SM; Knight P; McGorum BC; Pemberton AD
Clin Exp Allergy; 2006 Oct; 36(10):1303-9. PubMed ID: 17014440
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of tryptase as mast cell-stabilizing agents in the human airways: effects of tryptase and other agonists of proteinase-activated receptor 2 on histamine release.
He S; Aslam A; Gaça MD; He Y; Buckley MG; Hollenberg MD; Walls AF
J Pharmacol Exp Ther; 2004 Apr; 309(1):119-26. PubMed ID: 14722328
[TBL] [Abstract][Full Text] [Related]
26. Highly potent and selective substrate analogue factor Xa inhibitors containing D-homophenylalanine analogues as P3 residue: part 2.
Stürzebecher A; Dönnecke D; Schweinitz A; Schuster O; Steinmetzer P; Stürzebecher U; Kotthaus J; Clement B; Stürzebecher J; Steinmetzer T
ChemMedChem; 2007 Jul; 2(7):1043-53. PubMed ID: 17541992
[TBL] [Abstract][Full Text] [Related]
27. Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.
Sutton JC; Bolton SA; Davis ME; Hartl KS; Jacobson B; Mathur A; Ogletree ML; Slusarchyk WA; Zahler R; Seiler SM; Bisacchi GS
Bioorg Med Chem Lett; 2004 May; 14(9):2233-9. PubMed ID: 15081015
[TBL] [Abstract][Full Text] [Related]
28. Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase beta.
Sommerhoff CP; Avrutina O; Schmoldt HU; Gabrijelcic-Geiger D; Diederichsen U; Kolmar H
J Mol Biol; 2010 Jan; 395(1):167-75. PubMed ID: 19852971
[TBL] [Abstract][Full Text] [Related]
29. Structure-activity relationship of marinostatin, a serine protease inhibitor isolated from a marine organism.
Taichi M; Yamazaki T; Kawahara K; Motooka D; Nakamura S; Harada S; Teshima T; Ohkubo T; Kobayashi Y; Nishiuchi Y
J Pept Sci; 2010 Jul; 16(7):329-36. PubMed ID: 20552565
[TBL] [Abstract][Full Text] [Related]
30. Tryptase inhibitors: a patent review.
Ni WW; Cao MD; Huang W; Meng L; Wei JF
Expert Opin Ther Pat; 2017 Aug; 27(8):919-928. PubMed ID: 28425830
[TBL] [Abstract][Full Text] [Related]
31. Structure based design of 4-(3-aminomethylphenyl)piperidinyl-1-amides: novel, potent, selective, and orally bioavailable inhibitors of betaII tryptase.
Levell J; Astles P; Eastwood P; Cairns J; Houille O; Aldous S; Merriman G; Whiteley B; Pribish J; Czekaj M; Liang G; Maignan S; Guilloteau JP; Dupuy A; Davidson J; Harrison T; Morley A; Watson S; Fenton G; McCarthy C; Romano J; Mathew R; Engers D; Gardyan M; Sides K; Kwong J; Tsay J; Rebello S; Shen L; Wang J; Luo Y; Giardino O; Lim HK; Smith K; Pauls H
Bioorg Med Chem; 2005 Apr; 13(8):2859-72. PubMed ID: 15781396
[TBL] [Abstract][Full Text] [Related]
32. Definition of the extended substrate specificity determinants for beta-tryptases I and II.
Harris JL; Niles A; Burdick K; Maffitt M; Backes BJ; Ellman JA; Kuntz I; Haak-Frendscho M; Craik CS
J Biol Chem; 2001 Sep; 276(37):34941-7. PubMed ID: 11438529
[TBL] [Abstract][Full Text] [Related]
33. Designed calix[8]arene-based ligands for selective tryptase surface recognition.
Mecca T; Consoli GM; Geraci C; Cunsolo F
Bioorg Med Chem; 2004 Oct; 12(19):5057-62. PubMed ID: 15351389
[TBL] [Abstract][Full Text] [Related]
34. Structure-based library design and the discovery of a potent and selective mast cell β-tryptase inhibitor as an oral therapeutic agent.
Liang G; Aldous S; Merriman G; Levell J; Pribish J; Cairns J; Chen X; Maignan S; Mathieu M; Tsay J; Sides K; Rebello S; Whitely B; Morize I; Pauls HW
Bioorg Med Chem Lett; 2012 Jan; 22(2):1049-54. PubMed ID: 22192588
[TBL] [Abstract][Full Text] [Related]
35. Synthesis of potent and highly selective inhibitors of human tryptase.
Slusarchyk WA; Bolton SA; Hartl KS; Huang MH; Jacobs G; Meng W; Ogletree ML; Pi Z; Schumacher WA; Seiler SM; Sutton JC; Treuner U; Zahler R; Zhao G; Bisacchi GS
Bioorg Med Chem Lett; 2002 Nov; 12(21):3235-8. PubMed ID: 12372541
[TBL] [Abstract][Full Text] [Related]
36. Human beta-tryptase: detection and characterization of the active monomer and prevention of tetramer reconstitution by protease inhibitors.
Fukuoka Y; Schwartz LB
Biochemistry; 2004 Aug; 43(33):10757-64. PubMed ID: 15311937
[TBL] [Abstract][Full Text] [Related]
37. A role for tryptase in the activation of human mast cells: modulation of histamine release by tryptase and inhibitors of tryptase.
He S; Gaça MD; Walls AF
J Pharmacol Exp Ther; 1998 Jul; 286(1):289-97. PubMed ID: 9655871
[TBL] [Abstract][Full Text] [Related]
38. Monocharged inhibitors of mast cell tryptase derived from potent and selective dibasic inhibitors.
Dener JM; Wang VR; Rice KD; Gangloff AR; Kuo EY; Newcomb WS; Putnam D; Wong M
Bioorg Med Chem Lett; 2001 Sep; 11(17):2325-30. PubMed ID: 11527724
[TBL] [Abstract][Full Text] [Related]
39. Formation of active monomers from tetrameric human beta-tryptase.
Fajardo I; Pejler G
Biochem J; 2003 Feb; 369(Pt 3):603-10. PubMed ID: 12387726
[TBL] [Abstract][Full Text] [Related]
40. Expression and characterization of recombinant gamma-tryptase.
Yuan J; Beltman J; Gjerstad E; Nguyen MT; Sampang J; Chan H; Janc JW; Clark JM
Protein Expr Purif; 2006 Sep; 49(1):47-54. PubMed ID: 16815034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
